September 2017 - Cancer Currents Blog
-
Kids First Pediatric Research Program Moves ForwardProgress continues to be made with the Gabriella Miller Kids First Research Program, which is creating opportunities for investigators from different research communities to share resources and collaborate on research into childhood cancers and certain birth defects.
-
Gemtuzumab Receives New FDA Approval for Acute Myeloid LeukemiaFDA has approved gemtuzumab ozogamicin (Mylotarg™) for adults with newly diagnosed CD33-positive AML and patients 2 years and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.
-
Low-Tech Outreach Methods Improve Colorectal Cancer ScreeningProactive, low-tech outreach approaches can help increase the number of people who get screened for colorectal cancer with a colonoscopy or home stool test and complete the appropriate follow-up.
-
FDA Expands Approval of Fulvestrant for Advanced Breast CancerFDA has expanded its approval of fulvestrant (Faslodex®) as a standalone treatment for postmenopausal women with advanced HR-positive, HER2-negative breast cancer who have not previously undergone endocrine therapy.
-
Overcoming the Challenges of Metastatic Cancer: An Interview with Dr. Rosandra KaplanNCI’s Dr. Rosandra Kaplan discusses important trends in metastatic cancer research and new ideas for treating and preventing metastatic cancer.
-
Long-Term Nerve Damage Possible after Chemotherapy for Breast CancerMany women who receive taxane-based chemotherapy to treat breast cancer experience long-term nerve damage, or peripheral neuropathy, data from a large clinical trial show.
-
FDA Approves Inotuzumab for Adults with B-Cell Acute Lymphoblastic LeukemiaFDA has approved inotuzumab (Besponsa®) for some adults with B-cell acute lymphoblastic leukemia (ALL). The approval covers patients with B-cell ALL whose disease has relapsed or is refractory to standard chemotherapy.
-
FDA Approves Olaparib as Maintenance Therapy for Recurrent Ovarian CancerFDA has granted regular approval to olaparib tablets (Lynparza®) as maintenance treatment for patients with recurrent ovarian cancer who are having partial or complete responses to platinum-based chemotherapy.
-
Forgoing Conventional Cancer Treatments for Alternative Medicine Increases Risk of DeathIn a large study, patients with nonmetastatic breast, lung, or colorectal cancer who chose alternative therapies had substantially worse survival than patients who received conventional cancer treatments.
-
CAR T-Cell Therapy Approved for Some Children and Young Adults with LeukemiaFDA has approved tisagenlecleucel (Kymriah™), a type of immunotherapy called CAR T-cell therapy, for some children and young adults with advanced acute lymphoblastic leukemia (ALL).
-
Crizotinib Shows Promise for Childhood CancersIn a small clinical trial, the drug crizotinib shrank tumors in children with cancers that have alterations in the ALK gene.
-
New on NCI’s Websites for September 2017NCI periodically provides updates on new websites and other online content of interest to the cancer community.